-
1
-
-
3543002754
-
Relevant issues in bacterial vaccine development for patients with cystic fibrosis [abstract]
-
Döring G. Relevant issues in bacterial vaccine development for patients with cystic fibrosis [abstract]. Pedaitric Pulmonology 2003;Suppl 25:128-9.
-
(2003)
Pedaitric Pulmonology
, pp. 128-129
-
-
Döring, G.1
-
2
-
-
0031063067
-
A multicenter trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis
-
Döring G, Dorner F. A multicenter trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Institute Mitteilungen 1997;98:338-44.
-
(1997)
Behring Institute Mitteilungen
, vol.98
, pp. 338-344
-
-
Döring, G.1
Dorner, F.2
-
3
-
-
34547432470
-
A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients
-
Döring G, Meisner C, Stern M, for the Flagella Vaccine Trial Study Group. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proceedings of the National Academy of Science USA 2007;104:11020-5.
-
(2007)
Proceedings of the National Academy of Science USA
, vol.104
, pp. 11020-11025
-
-
Döring, G.1
Meisner, C.2
Stern, M.3
-
4
-
-
85041728765
-
Clinical trial protocol, No. KV 9909. Double-blind, randomised, placebo-controlled, multi-centre trial to determine the efficacy of Aerugen Berna Vaccine to prevent respiratory tract infections with P. aeruginosa in non-colonised patients with cystic fibrosis
-
2000 (May)
-
Clinical trial protocol, No. KV 9909. Double-blind, randomised, placebo-controlled, multi-centre trial to determine the efficacy of Aerugen Berna Vaccine to prevent respiratory tract infections with P. aeruginosa in non-colonised patients with cystic fibrosis. Medical Department, Swiss Serum and Vaccine Institute, Bern 2000 (May).
-
Medical Department, Swiss Serum and Vaccine Institute, Bern
-
-
-
5
-
-
85041742897
-
Crucell announces suspension of Aerugen(R) clinical development
-
(accessed 19 Dec)
-
Press release. Crucell announces suspension of Aerugen(R) clinical development. http://cws.huginonline.com/C/132631/PR/200607/1064252_5.html (accessed 19 Dec 2007).
-
(2007)
-
-
-
10
-
-
0021711007
-
Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis - three year results
-
Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis - three year results. Archives of Disease in Childhood 1984;59(12):1131-4.
-
(1984)
Archives of Disease in Childhood
, vol.59
, Issue.12
, pp. 1131-1134
-
-
Langford, D.T.1
Hiller, J.2
-
12
-
-
85041717924
-
Early trials of Pseudomonas vaccine in Cystic Fibrosis [abstract]
-
1970 April 29; Atlantic City
-
Gibbs GE. Early trials of Pseudomonas vaccine in Cystic Fibrosis [abstract]. Proceedings of the 11th Annual Meeting Cystic Fibrosis Club; 1970 April 29; Atlantic City. 1970:14.
-
(1970)
Proceedingsof the 11th Annual Meeting Cystic Fibrosis Club
, pp. 14
-
-
Gibbs, G.E.1
-
13
-
-
0031063093
-
Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-Polysaccharide-Toxin A conjugate vaccine
-
Cryz SJ, Lang A, Rudeberg A, Wedgewood J, Que JU, Furer E, et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-Polysaccharide-Toxin A conjugate vaccine. Behring Institute Mitteilungen 1997;98:345-9.
-
(1997)
Behring Institute Mitteilungen
, vol.98
, pp. 345-349
-
-
Cryz, S.J.1
Lang, A.2
Rudeberg, A.3
Wedgewood, J.4
Que, J.U.5
Furer, E.6
-
14
-
-
55049092231
-
Longterm protection against Pseudomonas aeruginosa (PA) infections in patients with cystic fibrosis (CF): results of a 9-year vaccine study [abstract]
-
Lang AB, Rudeberg A, Que JU, Wedgewood J, Furer E, Schaad UB, et al. Longterm protection against Pseudomonas aeruginosa (PA) infections in patients with cystic fibrosis (CF): results of a 9-year vaccine study [abstract]. Netherlands Journal of Medicine 1999;54(Suppl):s49.
-
(1999)
Netherlands Journal of Medicine
, vol.54
, pp. s49
-
-
Lang, A.B.1
Rudeberg, A.2
Que, J.U.3
Wedgewood, J.4
Furer, E.5
Schaad, U.B.6
-
15
-
-
55049083252
-
Ten years experience with a new O-polysaccharide conjugate vaccine in patients with cystic fibrosis [abstract]
-
2000 June 4-8; Stockholm
-
Lang AB, Rudeberg A, Wedgewood J, Que JU, Furer E, Schaad UB. Ten years experience with a new O-polysaccharide conjugate vaccine in patients with cystic fibrosis [abstract]. Proceedings of the XIIIth International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. 2000:170.
-
(2000)
Proceedingsof the XIIIth International Cystic Fibrosis Congress
, pp. 170
-
-
Lang, A.B.1
Rudeberg, A.2
Wedgewood, J.3
Que, J.U.4
Furer, E.5
Schaad, U.B.6
-
16
-
-
3042638668
-
Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection
-
Lang AB, Ruedeberg A, Schöni MH, Que JU, Furer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatric Infectious Disease Journal 2004;23(6):504-10.
-
(2004)
Pediatric Infectious Disease Journal
, vol.23
, Issue.6
, pp. 504-510
-
-
Lang, A.B.1
Ruedeberg, A.2
Schöni, M.H.3
Que, J.U.4
Furer, E.5
Schaad, U.B.6
-
17
-
-
0025950064
-
Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis
-
Schaad UB, Lang AB, Wedgewood J, Rudeberg A, Que JU, Furer E, et al. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991;338(8777):1236-7.
-
(1991)
Lancet
, vol.338
, Issue.8777
, pp. 1236-1237
-
-
Schaad, U.B.1
Lang, A.B.2
Wedgewood, J.3
Rudeberg, A.4
Que, J.U.5
Furer, E.6
-
18
-
-
0002236565
-
Immunology of cystic fibrosis
-
London: Chapman & Hall Medical
-
Döring G, Bellon G, Knight R. Immunology of cystic fibrosis. Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
-
(1995)
Cystic Fibrosis
-
-
Döring, G.1
Bellon, G.2
Knight, R.3
-
19
-
-
0033773012
-
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
-
Döring G, Conway SP, Heijerman HGM, Hodson M, Høiby N, Smyth A, Touw DJ for the Consensus Committee. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 2000;16(4):749-67.
-
(2000)
European Respiratory Journal
, vol.16
, Issue.4
, pp. 749-767
-
-
Döring, G.1
Conway, S.P.2
Heijerman, H.G.M.3
Hodson, M.4
Høiby, N.5
Smyth, A.6
-
20
-
-
3343023861
-
Early intervention and prevention of lung disease in cystic fibrosis: a European consensus
-
Döring G, Høiby N for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. Journal of Cystic Fibrosis 2004;3(2):67-91.
-
(2004)
Journal of Cystic Fibrosis
, vol.3
, Issue.2
, pp. 67-91
-
-
Döring, G.1
-
21
-
-
0041876133
-
Measuring inconsistency in meta-analyses
-
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
-
(2003)
BMJ
, vol.327
, Issue.7414
, pp. 557-560
-
-
Higgins, J.P.T.1
Thompson, S.G.2
Deeks, J.J.3
Altman, D.G.4
-
23
-
-
0002414405
-
Microbiology of cystic fibrosis
-
In: Hodson ME, Geddes DM editor(s). London: Chapman & Hall Medical
-
Høiby N. Microbiology of cystic fibrosis. In: Hodson ME, Geddes DM editor(s). Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
-
(1995)
Cystic Fibrosis
-
-
Høiby, N.1
-
24
-
-
0033653318
-
Prospective for the prevention and control of Pseudomonas infection in children with cystic fibrosis
-
Høiby N. Prospective for the prevention and control of Pseudomonas infection in children with cystic fibrosis. Pediatric Drugs 2000;2(6):451-63.
-
(2000)
Pediatric Drugs
, vol.2
, Issue.6
, pp. 451-463
-
-
Høiby, N.1
-
25
-
-
0029088951
-
Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats
-
Johansen HK, Hougen HR, Cryz SJ Jr, Rygaard J, Høiby N. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. American Journal of Respiratory and Critical Care Medicine 1995;152(4 Pt 1):1337-46.
-
(1995)
American Journal of Respiratory and Critical Care Medicine
, vol.152
, Issue.4
, pp. 1337-1346
-
-
Johansen, H.K.1
Hougen, H.R.2
Cryz, S.J.3
Rygaard, J.4
Høiby, N.5
-
26
-
-
0002382384
-
The epidemiology of cystic fibrosis
-
In: Hodson ME, Geddes D editor(s). London: Chapman and Hall
-
Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, Geddes D editor(s). Cystic Fibrosis. London: Chapman and Hall, 1995:1-13.
-
(1995)
Cystic Fibrosis
, pp. 1-13
-
-
Lewis, P.A.1
-
27
-
-
0033937232
-
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type
-
Moser C, Kjaergaard S, Pressler T, Kharazmi A, Koch C, Høiby N. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. Acta Pathologica, Microbiologica et Immunologica Scandinavia 2000;108(5):329-35.
-
(2000)
Acta Pathologica, Microbiologica et Immunologica Scandinavia
, vol.108
, Issue.5
, pp. 329-335
-
-
Moser, C.1
Kjaergaard, S.2
Pressler, T.3
Kharazmi, A.4
Koch, C.5
Høiby, N.6
-
28
-
-
0029849044
-
Reduced IL-10 secretion by CD4+T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR)
-
Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, et al. Reduced IL-10 secretion by CD4+T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clinical and Experimental Immunology 1996;106(2):374-88.
-
(1996)
Clinical and Experimental Immunology
, vol.106
, Issue.2
, pp. 374-388
-
-
Moss, R.B.1
Bocian, R.C.2
Hsu, Y.P.3
Dong, Y.J.4
Kemna, M.5
Wei, T.6
-
29
-
-
85047692188
-
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
-
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
-
(1995)
JAMA
, vol.273
, Issue.5
, pp. 408-412
-
-
Schulz, K.F.1
Chalmers, I.2
Hayes, R.J.3
Altman, D.G.4
-
30
-
-
0000963297
-
The Pathology of Cystic Fibrosis
-
In: Hodson ME, Geddes DM editor(s). London: Chapman & Hall Medical
-
Sheppard MN. The Pathology of Cystic Fibrosis. In: Hodson ME, Geddes DM editor(s). Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
-
(1995)
Cystic Fibrosis
-
-
Sheppard, M.N.1
-
31
-
-
0021270246
-
Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study
-
Wheeler WB, Williams RN, Matthews WJ, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. Journal of Pediatrics 1984;104(5):695-9.
-
(1984)
Journal of Pediatrics
, vol.104
, Issue.5
, pp. 695-699
-
-
Wheeler, W.B.1
Williams, R.N.2
Matthews, W.J.3
Colten, H.R.4
-
33
-
-
84891705714
-
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
-
Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD001399.pub3]
-
(2013)
Cochrane Database of Systematic Reviews
, Issue.6
-
-
Johansen, H.K.1
Gøtzsche, P.C.2
-
34
-
-
84991267415
-
Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis
-
Keogan MT, Johansen HK. Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001399]
-
(1999)
Cochrane Database of Systematic Reviews
, Issue.1
-
-
Keogan, M.T.1
Johansen, H.K.2
|